Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Table 4

Single factor analysis of adverse effect.

Characteristic		AE		χ2
		No	Yes
		(%)	(%)
Total AE
Age	≤3 months	165 (44.7)	43 (61.4)	6.592	0.007^#
	>3 months	204 (55.3)	27 (38.6)
Gender	Female	252 (68.3)	49 (70.0)	0.08	0.782
	Male	117 (31.7)	21 (30.0)
Medical history	No	327 (88.6)	67 (95.7)		0.366
	Preterm birth	30 (8.1)	2 (2.9)
	Others	7 (1.9)	1 (1.4)
	Heart disease	5 (1.4)	0 (0)
Location	Trunk/extremities	143 (38.8)	27 (38.6)	1.651	0.438
	Head/neck	194 (52.6)	40 (57.1)
	Perineum/female breast	32 (8.7)	3 (4.3)
GI symptom
Age	≤3 months	180 (46.0)	28 (58.3)	2.593	0.126
	>3 months	211 (54.0)	20 (41.7)
Gender	Female	270 (69.1)	31 (64.6)	0.396	0.621
	Male	121 (30.9)	17 (35.4)
Medical history	No	348 (89.0)	46 (95.8)		0.768
	Preterm birth	30 (7.7)	2 (4.2)
	Others	8 (2.0)	0 (0)
	Heart disease	5 (1.3)	0 (0)
Location	Trunk/extremities	150 (38.4)	20 (41.7)	1.107	0.617
	Head/neck	208 (53.2)	26 (54.2)
	Perineum/female breast	33 (8.4)	2 (4.2)
CNS symptom
Age	≤3 months	191 (45.9)	17 (73.9)	6.854	0.010^#
	>3 months	225 (54.1)	6 (26.1)
Gender	Female	284 (68.3)	17 (73.9)	0.322	0.651
	Male	132 (31.7)	6 (26.1)
Medical history	No	372 (89.4)	22 (95.7)		0.329
	Preterm birth	32 (7.7)	0 (0)
	Others	7 (1.7)	1 (4.3)
	Heart disease	5 (1.2)	0(0)
Location	Trunk/extremities	162 (38.9)	8 (34.8)	0.758	0.717
	Head/neck	220 (52.9)	14 (60.9)
	Perineum/female breast	34 (8.2)	1 (4.3)

Fisher probabilities in 2 × 2 table data, ^#.